Vaccines for sars-cov-2, different strategies of ongoing developments

Article Sidebar

PDF (Spanish)
Published: 2020-06-30
DOI: https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v40i2.484
Keywords:
SARS-Cov-2 vaccine, vaccine platform, COVID-19 strategy, attenuated virus, viral vector, viral proteins, viral DNA, viral RNA, nucleic acids, viral like particles, WHO

Main Article Content

Aída Edith Sterin Prync
Biotecnología. Departamento de Bioquímica Aplicada. Carrera Bioquímica. Instituto Universitario del Hospital Italiano de Buenos Aires, Argentina

Abstract

The objective of this article is to provide a guide to help the interpretation and monitoring the efforts that are being carried out worldwide to obtain a vaccine that will be able to generate immunity against the new 2019 SARS-CoV-2 coronavirus, the viral agent causes the disease named COVID-19. Five months after the disease was detected, there are already 102 vaccines at different stages of development, registered by World Health Organization (WHO), corresponding to 8 vaccination platforms base on different strategies, and every day new ones appear. This will represent a huge challenge for international organizations, to evaluate, compare and selects those that will meet the essential regulatory criteria of safety and efficacy and that, would be able to be produced in enough quantities to supply the worldwide demand

Downloads

Download data is not yet available.

Article Details

Issue

Vol. 40 No. 2 (2020): Revista del Hospital Italiano de Buenos Aires

Section

Update and advances in research
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

1.
Sterin Prync AE. Vaccines for sars-cov-2, different strategies of ongoing developments. Rev Hosp Ital B.Aires [Internet]. 2020 Jun. 30 [cited 2026 Jun. 6];40(2):63-75. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/484

References

World Health Organization. Draft landscape of COVID 19 candidate vaccines [Internet]. Geneva: World Health Organization; 2020 May 5 [citado 2020 Mayo 4]. Disponible desde: URL: https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines.

Chen WH, Strych U, Hotez PJ, et al. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep [Internet]. 2020 Mar 3 [citado 2020 abril 24]:1-4. Disponible en: https://doi.org/10.1007/s40475-020-00201-6. DOI: https://doi.org/10.1007/s40475-020-00201-6

Callaway E. Scores of coronavirus vaccines are in competition - how will scientists choose the best? Nature [Internet]. 2020 Apr 30 [citado 2020 abril 28]. Disponible en: https://doi.org/10.1038/d41586-020-01247-2. DOI: https://doi.org/10.1038/d41586-020-01247-2

Zhang J, Zeng H, Gu J, et al. Progress and prospects on vaccine development against sars-cov-2. Vaccines. 2020; 8(2):1-12. DOI: https://doi.org/10.3390/vaccines8020153

Callaway E. Scores of coronavirus vaccines are in competition - how will scientists choose the best? Nature. 2020. https://doi.org/10.1038/d41586-020-01247-2 DOI: https://doi.org/10.1038/d41586-020-01247-2

World Health Organization. An international randomised trial of candidate vaccines against COVID-19: outline of solidarity vaccine trial: version 9 April 2020 [Internet]. Geneva: WHO; 2020 [citado 2020 mayo 5]. Disponible en: https://www.who.int/blueprint/priority-diseases/keyaction/Outline_CoreProtocol_vaccine_trial_09042020.pdf.

World Health Organization. Criteria for COVID-19 vaccine prioritization: draft [Internet]. Geneva: WHO; 2020 April 28 [citado 2020 mayo 5]. Disponible en: https://www.who.int/who-documents-detail/criteria-for-covid-19-vaccine-prioritization.